Daniel M. Bradbury
Daniel M. Bradbury has been Chief Executive Officer at Amylin Pharmaceuticals, Inc. since March 2007, serving as President since June 2006, as Chief Operating Officer since June 2003, and director since June 2006. He previously served as Executive Vice President from June 2000 until his promotion in June 2003. He joined Amylin in 1994 and has held officer-level positions in Corporate Development and Marketing during that time. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, holding a number of sales and marketing positions. He is a member of the board of directors of Illumina, Inc., BIOCOM, and the San Diego Regional Economic Development Corporation. Bradbury serves on the UCSD Rady School of Management's Advisory Council, RAND Health Board of Advisors and University of Miami's Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education.